131 related articles for article (PubMed ID: 35905459)
1. Probability of Medication Intensifications in Rheumatoid Arthritis Patients With Low Disease Activity Scores on Their Patient-Reported Outcomes: A Medical-Records Review Study.
Seppen BF; Verkleij SJ; Wiegel J; Ter Wee MM; Nurmohamed MT; Bos WH
J Clin Rheumatol; 2022 Dec; 28(8):397-401. PubMed ID: 35905459
[TBL] [Abstract][Full Text] [Related]
2. The RAPID3 questionnaire as a screening tool to reduce the number of outpatient clinic visits: a retrospective cohort study.
Wiegel J; Seppen BF; Ter Wee MM; Nurmohamed MT; Boers M; Bos WH
Clin Rheumatol; 2022 Aug; 41(8):2525-2531. PubMed ID: 35469354
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of self-report questionnaires for assessing rheumatoid arthritis activity: a cross-sectional study of RAPID3 and RADAI5 and flare detection in 200 patients.
Bossert M; Prati C; Vidal C; Bongain S; Toussirot E; Wendling D
Joint Bone Spine; 2012 Jan; 79(1):57-62. PubMed ID: 21550283
[TBL] [Abstract][Full Text] [Related]
4. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
[TBL] [Abstract][Full Text] [Related]
5. The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA).
Barroso N; Woodworth TG; Furst DE; Guillemin F; Fautrel BJ; Borazan N; Kafaja S; Brook J; Elashoff DA; Ranganath VK
Clin Rheumatol; 2020 Jan; 39(1):189-199. PubMed ID: 31493148
[TBL] [Abstract][Full Text] [Related]
6. Flare Rate in Patients with Rheumatoid Arthritis in Low Disease Activity or Remission When Tapering or Stopping Synthetic or Biologic DMARD: A Systematic Review.
Kuijper TM; Lamers-Karnebeek FB; Jacobs JW; Hazes JM; Luime JJ
J Rheumatol; 2015 Nov; 42(11):2012-22. PubMed ID: 26428204
[TBL] [Abstract][Full Text] [Related]
7. Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice.
Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
RMD Open; 2019; 5(2):e001050. PubMed ID: 31908842
[TBL] [Abstract][Full Text] [Related]
8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
9. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories.
Pincus T; Swearingen CJ; Bergman M; Yazici Y
J Rheumatol; 2008 Nov; 35(11):2136-47. PubMed ID: 18793006
[TBL] [Abstract][Full Text] [Related]
10. One-year maintenance with routine assessment of patient index data 3-based remission may inhibit radiographic progression in patients with rheumatoid arthritis treated with routine clinical therapy: A retrospective comparison of radiographic outcome and its prognostic factors between maintained remissions with patient-reported outcome index and physician-oriented disease activity indices.
Katayama K; Okubo T; Sato T; Kamiya K; Fukai R; Abe S; Ito H; Makino Y; Kamishima T
Mod Rheumatol; 2016 Nov; 26(6):817-827. PubMed ID: 26915909
[TBL] [Abstract][Full Text] [Related]
11. Disease Burden in Osteoarthritis Is Similar to That of Rheumatoid Arthritis at Initial Rheumatology Visit and Significantly Greater Six Months Later.
Chua JR; Jamal S; Riad M; Castrejon I; Malfait AM; Block JA; Pincus T
Arthritis Rheumatol; 2019 Aug; 71(8):1276-1284. PubMed ID: 30891933
[TBL] [Abstract][Full Text] [Related]
12. Predictors for response to electronic patient-reported outcomes in routine care in patients with rheumatoid arthritis: a retrospective cohort study.
Wiegel J; Seppen BF; Nurmohamed MT; Ter Wee MM; Bos WH
Rheumatol Int; 2023 Apr; 43(4):651-657. PubMed ID: 36715728
[TBL] [Abstract][Full Text] [Related]
13. Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study.
Dougados M; Nataf H; Steinberg G; Rouanet S; Falissard B
Rheumatology (Oxford); 2013 Feb; 52(2):391-9. PubMed ID: 23104976
[TBL] [Abstract][Full Text] [Related]
14. Can RAPID3, an index without formal joint counts or laboratory tests, serve to guide rheumatologists in tight control of rheumatoid arthritis in usual clinical care?
Pincus T
Bull NYU Hosp Jt Dis; 2009; 67(3):254-66. PubMed ID: 19852747
[TBL] [Abstract][Full Text] [Related]
15. Barriers to treatment optimization and achievement of patients' goals: perspectives from people living with rheumatoid arthritis enrolled in the ArthritisPower registry.
Gavigan K; Nowell WB; Serna MS; Stark JL; Yassine M; Curtis JR
Arthritis Res Ther; 2020 Jan; 22(1):4. PubMed ID: 31910893
[TBL] [Abstract][Full Text] [Related]
16. The Clinical Disease Activity Index and the Routine Assessment of Patient Index Data 3 for Achievement of Treatment Strategies.
Kremer JM; Pappas DA; Kane K; Greenberg J; Harrold LR; Feathers VL; Shadick N; Weinblatt ME; Reed G
J Rheumatol; 2021 Dec; 48(12):1776-1783. PubMed ID: 33323534
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
[TBL] [Abstract][Full Text] [Related]
18. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
[TBL] [Abstract][Full Text] [Related]
19. Cost-effective Tapering Algorithm in Patients with Rheumatoid Arthritis: Combination of Multibiomarker Disease Activity Score and Autoantibody Status.
Hagen M; Englbrecht M; Haschka J; Reiser M; Kleyer A; Hueber A; Manger B; Figueiredo C; Cobra JF; Tony HP; Finzel S; Kleinert S; Wendler J; Schuch F; Ronneberger M; Feuchtenberger M; Fleck M; Manger K; Ochs W; Lorenz HM; Nüsslein H; Alten R; Henes J; Krüger K; Schett G; Rech J
J Rheumatol; 2019 May; 46(5):460-466. PubMed ID: 30504510
[TBL] [Abstract][Full Text] [Related]
20. Adherence to combination DMARD therapy and treatment outcomes in rheumatoid arthritis: a longitudinal study of new and existing DMARD users.
Wabe N; Lee A; Wechalekar M; McWilliams L; Proudman S; Wiese M
Rheumatol Int; 2017 Jun; 37(6):897-904. PubMed ID: 28160071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
